Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 20/20 | 1.00 |
| ▸ | NQO2 | P16083 | 1/20 | 0.52 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.52 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.52 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9105292 | 1.00 | MET (1.00) | METNQO2PDE3BPDE3APIP4K2C | |
| SCHEMBL9105275 | 1.00 | MET (1.00) | METNQO2PDE3BPDE3APIP4K2C | |
| SCHEMBL9105942 | 0.88 | MET (0.78) | METNQO2PDE3BPDE3APIP4K2C | |
| SCHEMBL9105922 | 0.88 | MET (0.78) | METNQO2PDE3BPDE3APIP4K2C | |
| SCHEMBL9105934 | 0.88 | MET (0.78) | METNQO2PDE3BPDE3APIP4K2C | |
| SCHEMBL1163405 | 0.81 | MET (0.74) | METNQO2PDE3BPDE3APIP4K2C | |
| SCHEMBL9101737 | 0.79 | MET (1.00) | MET | |
| SCHEMBL9101765 | 0.79 | MET (1.00) | MET | |
| SCHEMBL9101760 | 0.79 | MET (1.00) | MET | |
| SCHEMBL6524470 | 0.77 | MET (0.68) | MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497368-B2 | Heterocyclic hydrazone compounds | NOVARTIS AG (CH) | 2013-07-30 | — | — | US | disclosed |
| US-20120142681-A1 | HETEROCYCLIC HYDRAZONE COMPOUNDS | NOVARTIS AG (CH) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142681-A1 | HETEROCYCLIC HYDRAZONE COMPOUNDS | MET, HGF, RET | MET 1/4885NQO2 3372/4885PDE3B 2091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.